Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Seeking Alpha
Pemvidutide's dual GLP-1/glucagon mechanism targets both metabolic and liver endpoints, with ongoing trials in MASH, obesity, and alcohol use disorder. ALT's $285M pro forma cash position supports a 3–3.5 year runway, enabling late-stage development despite a projected annual burn of $80–85M. Key risks are lengthy Phase 3 timelines and slow patient recruitment; lack of Big Pharma partnership reflects regulatory and development-stage uncertainties. defun/iStock via Getty Images Thesis As you know, Altimmune, Inc. ( ALT ) has just announced the closing of a $75 million registered direct offering. They ended up issuing about 17 million shares of common stock and pre-funded warrants to a This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiv
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]Yahoo! Finance
- Altimmune Announces Closing of $75 Million Registered Direct Offering of Common StockGlobeNewswire
- Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell RestorationPR Newswire
- Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common StockGlobeNewswire
ALT
Earnings
- 11/6/25 - Beat
ALT
Sec Filings
- 2/3/26 - Form 4
- 2/3/26 - Form 8-K
- 2/2/26 - Form 4
- ALT's page on the SEC website